Can I Increase NAD+ Based on My Genetics? What the Evidence Shows

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on longevity and healthy aging. Browse all Longevity & Telomeres education

The NAD+ supplementation conversation has a genetics problem. Most of it is conducted as if NAD+ biology were the same in every person — as if NMN and NR work identically for everyone, as if the question is simply "how much should I take?" rather than "where is my specific metabolic bottleneck, and is precursor supplementation even addressing it?" The reality is that NAD+ homeostasis is governed by a web of genetically variable enzymes — enzymes that synthesize NAD+, enzymes that consume it, enzymes that recycle it, and enzymes that divert its precursors into competing pathways. Your NAD+ response to any intervention is substantially determined by which of those enzymes are genetically set to high or low activity in your biology. The PlexusDx Precision Peptide Genetic Test analyzes NAD+ pathway genetics as part of 14 pathways, 49 peptides, and 150+ genetic insights, mapping the individual genetic terrain that turns the generic NAD+ conversation into a biologically specific one.

How NAD+ Is Made, Used, and Recycled: The Three-Pathway Map

NAD+ homeostasis is maintained by three distinct biosynthetic routes, each with its own rate-limiting enzymes and genetic variable layer:

The Salvage Pathway — the dominant route in most human tissues. The salvage pathway recycles nicotinamide (Nam) — the breakdown product of NAD+ consumption by sirtuins, PARPs, and CD38 — back into NAD+. The rate-limiting enzyme is NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide to NMN (nicotinamide mononucleotide). NMNAT1, NMNAT2, and NMNAT3 then convert NMN to NAD+. NMN and NR (nicotinamide riboside) supplementation feeds into this pathway — NR is converted to NMN by NRK1/NRK2 kinases; NMN feeds directly into NMNAT. The efficiency of this entire salvage loop is substantially governed by NAMPT activity — making NAMPT the genetic master switch of NAD+ salvage capacity.

The de novo Kynurenine Pathway — synthesis from tryptophan. The de novo pathway converts dietary tryptophan through a series of enzymatic steps — indoleamine 2,3-dioxygenase (IDO1/IDO2), tryptophan 2,3-dioxygenase (TDO2), kynurenine aminotransferases, kynureninase (KYNU), 3-hydroxyanthranilic acid oxygenase (HAAO), and quinolinate phosphoribosyltransferase (QPRT) — into quinolinic acid, which is then converted to NMN and then to NAD+. This pathway is inefficient (approximately 60 mg of tryptophan produces 1 mg of niacin equivalent) but constitutively active, contributing a basal NAD+ production that is genetically modulated at multiple enzymatic steps — particularly QPRT, which is rate-limiting for the final conversion of quinolinic acid to NMN.

The Preiss-Handler Pathway — synthesis from niacin (NA). Dietary niacin (nicotinic acid) is converted to NAMN by NAPRT (nicotinic acid phosphoribosyltransferase), then through NMNAT to NAAD, then by NAD synthetase (NADSYN1) to NAD+. This pathway is highly efficient and bypasses NAMPT — which is why niacin supplementation raises NAD+ even in individuals with impaired NAMPT function. NAPRT expression varies by tissue type and is regulated by inflammatory signals; NADSYN1 genetic variants shape the final conversion step.

NAMPT: The Rate-Limiting Genetic Switch of NAD+ Salvage

NAMPT (nicotinamide phosphoribosyltransferase) is the enzyme that determines how efficiently the salvage pathway recycles nicotinamide back into NAD+. It exists in two forms: intracellular iNAMPT (the NAD+ biosynthetic enzyme in cells) and secreted eNAMPT (a cytokine with separate metabolic functions). iNAMPT activity is the primary determinant of cellular NAD+ levels in most tissues, including the brain, liver, muscle, and adipose tissue.

NAMPT expression and activity decline with age — one of the primary drivers of the NAD+ decline that begins in the fourth decade and accelerates progressively. Genetic variants in NAMPT that reduce enzyme expression or catalytic efficiency compound this age-related decline, producing lower NAD+ baselines at any given age compared to high-activity NAMPT carriers. Conversely, NAMPT variants associated with higher promoter activity maintain better NAD+ salvage capacity across the aging trajectory.

In the context of NAD+ precursor supplementation: both NMN and NR depend on NAMPT activity to efficiently recycle the nicotinamide generated from sirtuin and PARP-mediated NAD+ consumption. NMN feeds directly into the NMNAT step downstream of NAMPT — but the entire salvage cycle's efficiency, including the rate at which the nicotinamide produced from NMN metabolism is recycled, depends on NAMPT. Individuals with low-activity NAMPT genotypes may show attenuated NAD+ response to NMN or NR compared to high-activity NAMPT carriers — because the salvage cycle that these precursors amplify is operating at a lower enzymatic baseline.

CD38: The Largest NAD+ Consumer in Aging Tissue

Understanding why NAD+ falls with age requires understanding that declining synthesis is only half the story. The other half is accelerating consumption — and the primary accelerant is CD38 (cyclic ADP-ribose hydrolase), an NAD+-consuming enzyme expressed on immune cells, endothelium, and multiple other tissue types whose expression increases dramatically with age and with the chronic low-grade inflammation (inflammaging) that accompanies it.

CD38 consumes NAD+ at rates that dwarf sirtuin consumption by orders of magnitude — it is an extraordinarily efficient NAD+ hydrolase, producing ADPR (ADP-ribose) and NAM from NAD+ with a Km for NAD+ in the low micromolar range. In aged tissues with elevated CD38 expression, the NAD+-consuming activity of CD38 can exceed the entire NAD+ synthetic capacity of the salvage pathway — creating a net NAD+ deficit that no amount of NAMPT activity can fully compensate for.

Genetic variants that increase CD38 expression or reduce its regulatory suppression — through promoter polymorphisms, reduced miRNA-mediated post-transcriptional regulation, or variants in the transcription factor binding sites controlling CD38 expression — produce higher basal CD38 activity and greater NAD+ consumption pressure at any given age. For individuals with high-activity CD38 genotypes, NAD+ precursor supplementation is working against a larger ongoing hydrolysis current — requiring more precursor input to achieve equivalent NAD+ elevation.

Critically: flavonoids including apigenin, quercetin, and kuromanin have documented CD38 inhibitory activity, providing a complementary approach to NAD+ support that addresses consumption rather than production. The relevance of CD38 inhibition scales with CD38 genotype — higher CD38 activity genotypes receive more relative benefit from CD38 inhibition than lower-activity genotypes, for whom NAMPT salvage optimization may be the more relevant target.

NNMT: The NAD+ Precursor Methylation Diverter

A third genetic variable in NAD+ homeostasis that receives less clinical attention than NAMPT or CD38 is NNMT (nicotinamide N-methyltransferase) — the enzyme that methylates nicotinamide to form 1-methylnicotinamide, diverting NAM away from the NAMPT-mediated salvage pathway and toward renal excretion. NNMT competes directly with NAMPT for the same nicotinamide substrate — meaning high-activity NNMT reduces the nicotinamide available for salvage pathway recycling into NAD+.

NNMT is expressed primarily in liver and adipose tissue and is upregulated in obesity, metabolic syndrome, and high-fat dietary conditions. Genetic variants that increase NNMT expression — through promoter polymorphisms or reduced transcriptional suppression — produce chronically elevated nicotinamide methylation, diverting a larger fraction of available NAM away from NAMPT-mediated NAD+ synthesis. This NNMT-mediated NAM diversion also consumes SAM (S-adenosylmethionine) — the universal methyl donor — connecting NAD+ homeostasis to the broader methylation cycle that MTHFR genetics governs.

For individuals with high-activity NNMT genotypes, strategies that reduce NNMT-mediated nicotinamide diversion — including dietary and lifestyle interventions that reduce NNMT expression — are NAD+-relevant in a way that pure NAMPT/precursor approaches do not address. Knowing NNMT genotype identifies whether nicotinamide diversion is a significant contributor to NAD+ insufficiency, or whether the primary bottleneck is synthesis (NAMPT, QPRT) or overconsumption (CD38, PARP1).

PARP1: DNA Damage–Driven NAD+ Consumption

PARP1 (poly-ADP-ribose polymerase 1) is the DNA damage sensor that consumes NAD+ to generate poly-ADP-ribose chains at sites of DNA strand breaks — recruiting DNA repair machinery and initiating the repair response. Under normal conditions with minimal DNA damage, PARP1 consumes modest amounts of NAD+. Under conditions of high oxidative stress, UV exposure, chronic inflammation, or poor antioxidant genetics (SOD2, FOXO3 variants), PARP1 activation increases dramatically, consuming large amounts of NAD+ in proportion to the DNA damage burden.

PARP1 genetic variants that increase enzyme expression or PARP1 hyperactivation — including the well-documented Val762Ala (rs13181) variant that alters catalytic efficiency — shape baseline PARP1-mediated NAD+ consumption. Individuals with high PARP1 activity under oxidative stress lose more NAD+ per unit of DNA damage than low-activity PARP1 carriers. The PARP1 × SOD2 × FOXO3 interaction is particularly relevant here: poor antioxidant genetics produces more oxidative DNA damage → more PARP1 activation → more NAD+ consumed per cell → lower NAD+ baseline, which then reduces SIRT1 deacetylase activity, which reduces FOXO3 activation, which reduces SOD2 upregulation — a compounding cycle where antioxidant genetic insufficiency and NAD+ depletion amplify each other.

SIRT1: The NAD+-Dependent Deacetylase That Connects Everything

SIRT1 is the primary NAD+-consuming enzyme relevant to longevity — consuming one molecule of NAD+ per deacetylation reaction, with its activity directly and linearly dependent on available NAD+ concentration. SIRT1 deacetylates and activates PGC-1α (mitochondrial biogenesis), p53 (DNA damage response), NF-κB (inflammatory suppression), FOXO3 (stress response transcription), and dozens of other targets that collectively govern the cellular aging program.

SIRT1 genetic variants shape two NAD+-relevant dimensions:

SIRT1 expression and enzyme baseline. Promoter variants affecting SIRT1 transcription determine how much SIRT1 protein is present to consume NAD+ and execute deacetylation targets. High-expression SIRT1 genotypes have greater longevity-relevant deacetylase capacity — but also consume more NAD+ per unit time, increasing the NAD+ demand that NAMPT-mediated salvage must meet.

SIRT1 substrate sensitivity. Variants affecting the SIRT1 catalytic domain or its regulatory interactions shape the Km for NAD+ — how much NAD+ is required to achieve half-maximal SIRT1 activity. High-Km SIRT1 variants require more NAD+ to activate the deacetylase program, meaning NAD+ elevation through precursor supplementation must achieve higher absolute NAD+ concentrations before producing equivalent SIRT1 activation compared to low-Km variants.

Full SIRT1 genetics detail: The SIRT1 Pathway: Genetics, NAD+, and Cellular Repair.

The Kynurenine Pathway and Tryptophan-to-NAD+ Efficiency

The de novo NAD+ synthesis route from tryptophan contains multiple genetically variable enzymatic steps — particularly IDO1 (indoleamine 2,3-dioxygenase), TDO2 (tryptophan 2,3-dioxygenase), and QPRT (quinolinate phosphoribosyltransferase). IDO1 and TDO2 are the first-step enzymes that commit tryptophan to the kynurenine pathway rather than to serotonin synthesis or protein incorporation — their relative activity determines what fraction of available tryptophan is channeled toward NAD+ production.

QPRT is rate-limiting for the final step — converting quinolinic acid (a neuroexcitotoxic intermediate) to NMN and then to NAD+. Low QPRT activity allows quinolinic acid to accumulate — a situation relevant not only to NAD+ insufficiency but to neuroinflammation and neurotoxicity, since quinolinic acid is an NMDA receptor agonist. QPRT variants that reduce enzyme activity reduce de novo NAD+ synthesis efficiency from tryptophan while simultaneously allowing quinolinic acid accumulation — making QPRT genetics a dual variable relevant to both NAD+ homeostasis and neurological health.

Reading Your NAD+ Genetic Picture: Which Bottleneck Is Yours?

The practical question — can I increase NAD+ based on my genetics? — resolves into four possible primary bottleneck patterns, each pointing toward a different optimization emphasis:

Low NAMPT, normal CD38: Production-limited salvage pathway. NMN or NR supplementation directly addresses the rate-limiting step — feeding substrate into the NAMPT-downstream NMNAT reaction. Combined with NAMPT-activating lifestyle inputs (caloric restriction, exercise) that upregulate NAMPT expression.

Normal NAMPT, high CD38: Consumption-driven depletion. NAD+ precursor supplementation must overcome an elevated hydrolysis current. CD38 inhibition strategies — dietary flavonoids (apigenin, quercetin), reduction of the chronic inflammation driving CD38 upregulation — address the consuming side of the equation rather than the synthetic side alone.

High NNMT: Nicotinamide diversion deficit. A meaningful fraction of available NAM is being methylated toward excretion rather than recycled. Addressing NNMT overexpression requires the metabolic and dietary conditions that reduce NNMT expression — rather than simply increasing precursor input that is then partially diverted.

Low QPRT: De novo synthesis inefficiency. The tryptophan-to-NAD+ pathway is constrained at the quinolinic acid conversion step. Strategies that support QPRT activity and reduce quinolinic acid accumulation, alongside salvage pathway precursors, address both the NAD+ synthesis deficit and the quinolinic acid accumulation risk.

Identifying which pattern applies requires knowing the genetic status of multiple NAD+ pathway enzymes simultaneously — precisely what the Precision Peptide Genetic Test's 14-pathway structure enables. The complete longevity panel context is in the Complete Guide to Genetic Longevity Testing and The SIRT1 Pathway: Genetics, NAD+, and Cellular Repair.

The Precision Peptide Genetic Test analyzes how your genes influence longevity and aging pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to identify your NAD+ genetic bottleneck? Take the Precision Peptide Genetic Test

Frequently Asked Questions About NAD+ Genetics

Which gene most controls NAD+ levels in aging?

NAMPT is the rate-limiting enzyme of the NAD+ salvage pathway and the primary determinant of cellular NAD+ levels. NAMPT activity declines with age, compounded by genetic variants reducing enzyme expression. CD38 is the dominant NAD+ consumer, increasing with inflammaging. The Precision Peptide Genetic Test maps both within 14 pathways and 150+ insights.

Why might NMN or NR supplementation work differently for different people?

NAMPT genetic variants shape salvage pathway capacity — the loop NMN and NR feed into. High CD38 genotypes consume NAD+ faster, requiring more precursor input for equivalent elevation. High NNMT genotypes divert nicotinamide toward methylation rather than recycling. The Precision Peptide Genetic Test identifies your primary bottleneck across 14 pathways and 150+ genetic insights.

Does PARP1 genetics affect NAD+ supplementation response?

Yes — PARP1 consumes NAD+ at DNA damage sites, and variants like Val762Ala affect catalytic efficiency. Poor SOD2 or FOXO3 genetics increases oxidative DNA damage, driving PARP1 activation and NAD+ loss simultaneously. Reducing antioxidant genetic insufficiency addresses PARP1-driven depletion. The Precision Peptide Genetic Test maps PARP1 alongside SOD2 and FOXO3 within 14 pathways, 150+ insights.

This article is part of the PlexusDx Education Hub. Browse all Longevity & Telomeres education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.